Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pituitrin in early refractory septic shock
ChiCTR2400082478Phase 4Not yet recruiting
- Sponsor
- Subei People's Hospital
- Start
- Mar 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of pituitrin and hydrocortisone in septic shock (2 arms), sponsored by Subei People's Hospital. Primary endpoint: Response of mean arterial pressure at 3 hours after start of infusion. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
pituitrinhydrocortisone
03
Conditions
septic shock
Beyond the preview
Go deeper on ChiCTR2400082478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082478.